✦ LIBER ✦

Efficacy of scheduled infliximab maintenance therapy on systemic amyloidosis associated with crohn's disease

✍ Scribed by Masahiro Iizuka; Shiho Sagara; Takeshi Etou

Publisher: John Wiley and Sons
Year: 2011
Tongue: English
Weight: 91 KB
Volume: 17
Category: Article
ISSN: 1078-0998
DOI: 10.1002/ibd.21720

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy of infliximab in pediatric Croh

Efficacy of infliximab in pediatric Crohn's disease: A randomized multicenter open-label trial comparing scheduled to on demand maintenance therapy

✍ Frank M. Ruemmele; Alain Lachaux; Jean-Pierre Cézard; Alain Morali; Chantal Maur 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 156 KB 👁 1 views

## Background: Infliximab (ifx) is efficacious in inducing remission in severe forms of pediatric crohn's disease (cd). adult studies indicate that ifx is also safe and well tolerated as maintenance therapy. the present study aimed to evaluate in a prospective manner the efficacy and safety of ifx

Long-term outcome of maintenance inflixi

Long-term outcome of maintenance infliximab therapy in children with Crohn's disease

✍ Jeffrey S. Hyams; Trudy Lerer; Anne Griffiths; Marian Pfefferkorn; Subra Kugatha 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 218 KB 👁 2 views

Background: Infliximab therapy has short-term benefits in children with moderate-to-severe Crohn's disease (CD). We assessed the long-term outcome of infliximab maintenance therapy in children with CD. ## Methods: We performed a multicenter cohort study of 729 pediatric patients with CD enrolled i

Impact of prior irregular infliximab dos

Impact of prior irregular infliximab dosing on performance of long-term infliximab maintenance therapy in Crohn's disease

✍ Daniel J. Stein; Ashwin N. Ananthakrishnan; Mazen Issa; John B. Williams; Dawn B 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 285 KB 👁 1 views

## Background: Infliximab is efficacious in the management of moderate to severe crohn's disease (cd). there are limited data regarding performance of infliximab in patients who require reinitiation of maintenance dosing following previous irregular exposure. ## Methods: This was a retrospective,

Mucosal healing predicts long-term outco

Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease

✍ Fabian Schnitzler; Herma Fidder; Marc Ferrante; Maja Noman; Ingrid Arijs; Gert V 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 395 KB 👁 2 views

Background: Infliximab (IFX) treatment induces mucosal healing (MH) in patients with Crohn's disease (CD) but the impact of MH on the long-term outcome of IFX treatment in CD is still debated. ## Methods: We studied MH during long-term treatment with IFX in 214 CD patients. A total of 183 patients

Effects of infliximab therapy on abdomin

Effects of infliximab therapy on abdominal fat and metabolic profile in patients with Crohn's disease

✍ Erika Parmentier-Decrucq; Alain Duhamel; Olivier Ernst; Catherine Fermont; Alexa 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 224 KB

## Background: Tumor necrosis factor is an adipocytokine possessing a well-established lipolytic effect. in crohn's disease (cd) patients, infliximab therapy may thus result in visceral fat accumulation, which is associated with an increased risk of metabolic syndrome. ## Methods: A total of 132